Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Austin Gold (AUST)
Intensity Therapeutics (INTS)
Genenta Science (GNTA)
Chicago Atlantic Real Estate Finance, Inc. (REFT)
Chicago Atlantic Real Estate Finance (REFI)
Nu Holdings Ltd. (NU)
Hashicorp, Inc. (HCP)
Fresh Vine Wine, Inc. (VINE)
Priced IPO
AeroClean Technologies (AERC)
Finwise Bancorp (FINW)
Kindercare Learning Companies, Inc. (KLC)
Snow Lake Resources (LITM)
Sweetgreen, Inc. (SG)
Usertesting, Inc. (USER)
Braze, Inc. (BRZE)
Sono Group N.v. (SEV)
Iris Energy Limited (IREN)
Mynaric Ag (MYNA)
Journey Medical Corporation? (DERM)
Tivic Health Systems (TIVC)
Blackboxstocks (BLBX)
Kidpik (PIK)
Vaxxinity, Inc. (VAXX)
Lulus Fashion Lounge Holdings, Inc. (LVLU)
Weave Communications, Inc. (WEAV)
Backblaze, Inc. (BLZE)
HeartBeam, Inc. (BEAT)
Rivian Automotive, Inc. (RIVN)
More companies

Lianbio (LIAN)

Sector - Healthcare

Price chart

-36.81%
Return from IPO

Company News

IPO Profile

About company

They are a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. They have purposefully designed their organization to successfully execute on their vision by identifying, sourcing, developing and commercializing product candidates and partnering with highly innovative biopharmaceutical companies around the world. They are establishing an international infrastructure to position ourselves as a partner of choice with a platform to provide access to their target markets. Their model leverages a number of key elements, including transformative in-licensing, development and commercialization approaches that they believe will enable them to deliver innovative therapeutic solutions to patients in Greater China, including Mainland China, Hong Kong, Taiwan and Macau, and other Asian markets. Their deep relationships with their founder, Perceptive Advisors (“Perceptive”), as well as their broader investor base, position them to access and capture attractive business development opportunities. They have also entered into high-value strategic collaborations with Pfizer Inc. (“Pfizer”), which offers optionality to leverage its broad reach and commercial infrastructure in Greater China, and BridgeBio Pharma LLC (“BridgeBio”), which provides preferential access to an innovative pipeline of more than 20 product candidates in development.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
87 2019

Contacts

Address: 103 Carnegie Center Drive, Suite 215 Princeton, Nj 08540

Telephone: (609) 486-2308

Web page: http://www.lianbio.com

IPO information

First Trade Date 11/2/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 20.3
Shares Revised (MM) 20.3
Expected offer amount (MM) $324.8
Realized offer amount(MM) $324.8

Financial Data (last reporting year)

Market Cap (MM) $1684.11
Revenues (MM) $0
Net Income (Loss) (MM) $-294.97

Voting

What do you think will happen with the LIAN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Goldman Sachs

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Goldman Sachs/ Jefferies/ BofA Securities
CO-Managers
Raymond James

Sector: Healthcare

Tweets about $LIAN

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats